Haemonetics Corporation (NYSE:HAE) Repositions For Near-Term Margin Expansion And Higher-Quality Revenue
![]() |
Haemonetics enters a phase of earnings quality improvement and margin leverage while technical momentum supports further upside in the coming weeks. Near-term price direction depends on momentum continuation versus measured mean reversion pressure. |










